The 4 Pillars of a Successful Cell and Gene Therapy Launch

January 13, 2020

As part of our ongoing commitment to developing and supporting commercialization strategies for Cell and Gene Therapy (CGT) products, Archbow has been actively involved with the Bio Supply Management Alliance (BSMA.) 


At the BSMA annual meeting, Kevin Cast and Paul Furgal sat down with Devendra Mishra, Executive Director of BSMA, for an interview on what it takes to successfully launch a CGT product in today's marketplace. 


To learn more about the four pillars of a successful CGT launch and how traditional pharmaceutical distribution must be transformed to meet the challenges of these revolutionary therapies, read the full Q&A here.


If you're preparing to launch a CGT product and would like to tap into the resources and expertise Archbow Consulting has to offer, contact us today


Related Resource:  Cell and Gene Therapy Supply Chain Case Study - learn how a U.S. biotech company established a global supply chain for a cell therapy with complicated and unique characteristics.

Share on Facebook
Share on Twitter
Please reload

Featured Posts

How Pharma & Biotech Manufacturers Can Prepare for COVID-19 HCP Distribution Revenue Cycle Fallout

March 31, 2020

Please reload

Recent Posts

March 23, 2020

Please reload

Please reload

© 2020 by Archbow Consulting LLC | 355-2686

Privacy Policy